Dynamic Technology Lab Private Ltd purchased a new stake in Steris Corp. (NYSE:STE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 4,651 shares of the company’s stock, valued at approximately $320,000.
A number of other hedge funds have also recently added to or reduced their stakes in the company. American Century Companies Inc. boosted its stake in Steris Corp. by 870.8% in the second quarter. American Century Companies Inc. now owns 1,208,491 shares of the company’s stock valued at $83,084,000 after buying an additional 1,084,007 shares during the last quarter. Villere ST Denis J & Co. LLC purchased a new stake in Steris Corp. during the second quarter valued at $46,505,000. Bank of Montreal Can purchased a new stake in Steris Corp. during the second quarter valued at $22,429,000. Royal Bank of Canada boosted its stake in Steris Corp. by 109.5% in the first quarter. Royal Bank of Canada now owns 468,134 shares of the company’s stock valued at $33,261,000 after buying an additional 244,710 shares during the last quarter. Finally, Channing Capital Management LLC boosted its stake in Steris Corp. by 457.1% in the second quarter. Channing Capital Management LLC now owns 273,003 shares of the company’s stock valued at $18,769,000 after buying an additional 224,003 shares during the last quarter. 91.58% of the stock is owned by institutional investors and hedge funds.
Shares of Steris Corp. (NYSE:STE) traded down 0.27% during midday trading on Thursday, reaching $72.96. The company had a trading volume of 24,047 shares. The company has a market capitalization of $6.29 billion, a PE ratio of 41.91 and a beta of 1.16. Steris Corp. has a one year low of $61.38 and a one year high of $78.77. The company has a 50 day moving average of $71.26 and a 200 day moving average of $70.18.
Steris Corp. (NYSE:STE) last posted its earnings results on Tuesday, August 9th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.02. The firm had revenue of $638.40 million for the quarter, compared to the consensus estimate of $639.04 million. Steris Corp. had a return on equity of 10.72% and a net margin of 5.52%. The business’s quarterly revenue was up 45.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.62 earnings per share. Analysts predict that Steris Corp. will post $3.90 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 27th. Shareholders of record on Tuesday, August 30th were given a dividend of $0.28 per share. The ex-dividend date was Friday, August 26th. This represents a $1.12 annualized dividend and a dividend yield of 1.53%. This is an increase from Steris Corp.’s previous quarterly dividend of $0.25. Steris Corp.’s dividend payout ratio is currently 68.71%.
Several analysts recently weighed in on STE shares. Zacks Investment Research cut Steris Corp. from a “hold” rating to a “sell” rating in a report on Wednesday, September 14th. Northcoast Research raised Steris Corp. from a “neutral” rating to a “buy” rating in a report on Friday, June 3rd.
In other Steris Corp. news, Director Richard Martin Steeves sold 204,778 shares of the stock in a transaction on Wednesday, September 7th. The stock was sold at an average price of $71.19, for a total transaction of $14,578,145.82. Following the sale, the director now owns 165,434 shares in the company, valued at $11,777,246.46. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Adrian Vincent Coward sold 15,000 shares of the stock in a transaction on Wednesday, August 31st. The stock was sold at an average price of $69.00, for a total value of $1,035,000.00. The disclosure for this sale can be found here. Company insiders own 2.52% of the company’s stock.
About Steris Corp.
STERIS Corporation (STERIS) is a provider of infection prevention and other procedural products and services. The Company is focused on healthcare, pharmaceutical and research. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The Healthcare segment provides surgical, sterile processing, infection prevention and gastrointestinal solutions.
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Steris Corp. (NYSE:STE).
Receive News & Ratings for Steris Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Corp. and related companies with MarketBeat.com's FREE daily email newsletter.